{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.3","value":"225"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG001","spread":"NA","value":"642"},{"groupId":"OG002","spread":"61.7","value":"617"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"1120"},{"groupId":"OG004","spread":"27.5","value":"842"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Day 1: EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.7","value":"79.4"},{"groupId":"OG001","spread":"27.8","value":"110"},{"groupId":"OG002","spread":"49.3","value":"115"},{"groupId":"OG003","spread":"47.9","value":"139"},{"groupId":"OG004","spread":"38.3","value":"116"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.7","value":"37.5"},{"groupId":"OG001","spread":"37.3","value":"63.0"},{"groupId":"OG002","spread":"62.3","value":"69.6"},{"groupId":"OG003","spread":"18.9","value":"63.2"},{"groupId":"OG004","spread":"38.9","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.4","value":"31.0"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG001","spread":"NA","value":"33.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 6 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.3","value":"3.27"},{"groupId":"OG001","spread":"12.9","value":"5.91"},{"groupId":"OG002","spread":"54.0","value":"4.75"},{"groupId":"OG003","spread":"41.2","value":"5.51"},{"groupId":"OG004","spread":"57.7","value":"6.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 1: 24 hours"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"62.6","value":"0.519"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"78.8","value":"0.411"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 8: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.6","value":"318"},{"groupId":"OG001","spread":"17.1","value":"576"},{"groupId":"OG002","spread":"52.7","value":"829"},{"groupId":"OG003","spread":"41.1","value":"1360"},{"groupId":"OG004","spread":"45.4","value":"1070"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"title":"Cycle 1 Day 8: EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.8","value":"0.177"},{"groupId":"OG001","spread":"1139.8","value":"0.758"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Day 15: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.1","value":"281"},{"groupId":"OG001","spread":"41.8","value":"585"},{"groupId":"OG002","spread":"55.5","value":"812"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"830"},{"groupId":"OG004","spread":"24.6","value":"940"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Cycle 1 Day 15: EOI"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.1","value":"212"},{"groupId":"OG001","spread":"38.5","value":"844"},{"groupId":"OG002","spread":"61.6","value":"767"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"1580"},{"groupId":"OG004","spread":"8.7","value":"820"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 1: EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.9","value":"0.182"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG001","spread":"NA","value":"0.536"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"0.286"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Cycle 2 Day 15: Predose"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG000","spread":"NA","value":"191"},{"groupId":"OG002","spread":"46.3","value":"634"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"1500"},{"groupId":"OG004","spread":"14.2","value":"713"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 15: EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Observed plasma concentration of TAK-981 was reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received TAK-981 60 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 1b, Part 1: TAK-981 60 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG001","title":"Phase 1b, Part 1: TAK-981 90 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG002","title":"Phase 1b, Part 1: TAK-981 90 mg QW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG003","title":"Phase 1b, Part 1: TAK-981 120 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG004","title":"Phase 1b, Part 1: TAK-981 120 mg QW + Mezagitamab 600 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included participants with sufficient dosing and PK data to reliably estimate 1 or more PK parameters. Here \"number analyzed\" signifies participants evaluable at specified time-point.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: Pre-dose, at end of infusion (EOI), 2, 4, 6, and 24 hours post-dose; Cycle 1 Days 8 and 15: Pre-dose and EOI; Cycle 2 Days 1 and 15: Pre-dose and EOI (Cycle length = 28 days)","title":"Phase 1b, Part 1: Observed Plasma Concentration of TAK-981","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}